Drug Trial Radar · NCT07103655
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
132
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Nov 1, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.
Conditions
- Hypertrophic Cardiomyopathy (HCM)
Interventions
mavacamtenDrug
Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.
Beta Blocker (BB) - metoprolol, bisoprolol, carvedilolDrug
Administer an appropriate dose of beta-blockers according to the patient's tolerance.
diltiazemDrug
Administer an appropriate dose of diltiazem according to the patient's tolerance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in pressure gradient during the Valsalva maneuverTime frame: Week 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.